What Happened

NewLimit, a biotech startup focused on longevity, raised $435M in a Series C funding round led by Founders Fund. Thrive Capital and Lilly Ventures also participated. The company plans to launch its first clinical trial for a liver medicine and is now valued at $3.1B.

Who Is Affected

This funding impacts NewLimit’s stakeholders, including investors like Founders Fund, Thrive Capital, and Lilly Ventures. It also positions NewLimit as a key player in the longevity and liver health markets.

Market Impact

• NewLimit’s $3.1B valuation underscores investor confidence in longevity biotech.
• The upcoming clinical trial highlights advancements in liver health treatments.
• Increased funding accelerates NewLimit’s R&D and market presence.

What to Watch

Monitor NewLimit’s progress in its clinical trial and its ability to leverage its $435M funding to advance its pipeline. Watch for partnerships or collaborations in the longevity and liver health sectors.